Register for Upcoming Webinar on DEC. 8 @ 11AM

2024 China NMPA Bluebook is here:

Johnson & Johnson Medical Device Division: Materializing China’s Future Prospects and Growth Potential


In the second quarter of 2017, Johnson & Johnson (JNJ)’s US medical device sales grew 6.1%. Although JNJ faces stiff competition in China, its medical device sales in this emergent market still registered more than 10% in sales growth in this market in the same quarter.


JNJ has been making strong investments in emerging markets like China. Though there are some short term challenges in these geographies, the long-term market potential presents a significant opportunity.


Meanwhile, JNJ’s major competitors in medical device space, including Medtronic, Stryker and Abbott Laboratories, are also looking to expand their operations in emerging markets, given the immense growth potential. These companies are also continually striving to gain higher market shares through strategic collaboration, acquisitions, restructuring, and product launches.

China Med Device, LLC, specializing in providing turn-key solutions for medtech companies’ entry into China, brings you up-to-date information on medical industry trends in China and related regions. If you have any feedback or inquiry regarding any of our services from China market assessment, CFDA registration, to funding and growth and product commercialization in China, please email us at or visit us at

Have Questions?

Related Services


Recent Events

Related Posts


Get Updated

Receive Updates in Your Inbox